Research programme: T-cell adoptive immunotherapy - Cellectis

Drug Profile

Research programme: T-cell adoptive immunotherapy - Cellectis

Alternative Names: UCART 38; UCART-22; UCART-CS1

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier; University College London
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 03 Apr 2018 Allogene and Pfizer enter into an asset contribution agreement for allogeneic chimeric antigen receptor T-cell therapy iincluding 16 preclinical CAR-T assets
  • 12 Mar 2018 Cellectis plans to file an IND application with the US FDA in the first half of 2018
  • 12 Mar 2018 Cellectis plans a phase I trial for Acute lymphoblastic leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top